London Health Sciences Centre (LHSC) and St. Joseph’s Heath Care London (St. Joseph’s) are celebrating the installation of a Total Laboratory Automation (TLA) system within the clinical microbiology laboratory. The innovative and automated technology will assist highly skilled laboratory professionals, build lab capacity and enhance advanced detection of infectious diseases, generating high-quality results even faster. The TLA system is the first of its kind to be installed in the world, making London an international flagship site for innovation in clinical microbiology.
The clinical microbiology lab is part of the Pathology and Laboratory Medicine (PaLM), a joint venture of LHSC and St. Joseph’s providing a comprehensive range of routine and specialized testing and clinical consultation for patient care within Southwestern Ontario and beyond. “The automated system will allow us to accommodate increased volumes in diagnostic testing and innovations within the system will help optimize productivity of staff, test accuracy, and the time required to report a test result,” says Dr. Jeff Fuller, Division Head, Clinical Microbiology. “The TLA system’s innovative technology will facilitate the transformation of laboratory operations, allowing for future growth and sustainability.”
The BD Kiestra™ 3rd Generation TLA system automates bacterial culture investigations on patient specimens to transform laboratory operations. With integrated work benches and a newly designed track mechanism, BD Kiestra™ solutions deliver end-to-end automated workflows from plate labelling to inoculation, incubation, imaging, culture reading and results reporting. Located at LHSC’s Victoria Hospital (VH), the state-of-the-art microbiology lab and TLA system will serve hundreds of thousands of patients across London and Southwestern Ontario every year.
The importance of lab infrastructure was evident throughout the pandemic as a key enabler for health system readiness and future pandemic preparedness. The Microbiology Program, part of PaLM, provides advanced diagnostic services to LHSC, St. Joseph’s, and several other regional partners in the referral area for detecting and treating infectious diseases.
“This investment supports our vision of transforming health together within our walls and for patients across our region,” says John French, Clinical Diagnostics Executive, Laboratory Services and Medical Imaging at LHSC. “By making a targeted investment in the TLA system, LHSC is working to advance excellence in health care for better patient outcomes.”
“At St. Joseph’s, patient and resident safety is paramount and this state-of the-art technology is a vital investment in just that,” says Karen Perkin, Vice President Patient Care and Chief Nurse Executive, St. Joseph’s. “With growing demands on microbiology services, there is a tremendous need for innovative community based settings, including: St. Joseph’s Hospital; Parkwood Institute; Mount Hope Centre for Long Term Care; and the Southwest Centre for Forensic Mental Health Care. Learn more at sjhc.london.on.ca.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.